Renovacor Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Debuted as a public company and raised gross proceeds of $95.1 million from the business combination with Chardan Healthcare Acquisition 2 Corp and a concurrent PIPE financing
Strengthened company leadership with key appointments including Marc Semigran, M.D., as CMO, Matthew Killeen, Ph.D., as CSO and Elizabeth White, Ph.D., as CBO and SVP of Operations
Reported topline preclinical data demonstrating successful cardiac transduction with REN-001 delivered via local infusion at a low vector dose in a pilot pig study
Significant progress made across key ongoing REN-001 IND-enabling studies
IND submission for REN-001 is expected in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM anticipated to follow